Sayed M.S. Hashemi

Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

David Planchard, Benjamin Besse, Harry J.M. Groen et al. · Journal of Thoracic Oncology · 2021 · 269 citations · Full text

Medicine, Oncology, Pharmacology +14

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with “Ultracentral” Non–Small Cell Lung Cancer

H. Tekatli, N. Haasbeek, Max Dahele et al. · Journal of Thoracic Oncology · 2016 · 224 citations

Medicine, Oncology, Radiation Oncology +13

Association of Machine Learning–Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC

Mehrdad Rakaee, Elio Adib, Biagio Ricciuti et al. · JAMA Oncology · 2022 · 131 citations · Full text

Life Sciences, Immunology, Oncology +17

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer

Bianca van Veggel, Juliana F. Vilacha Madeira R Santos, Sayed M.S. Hashemi et al. · Lung Cancer · 2019 · 93 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +10